eXoZymes Insider Sales & IPO Reveal Strategic Boost for Exozyme Therapy Development
eXoZymes insider trades reveal a balanced strategy: CFO sales, upcoming Nasdaq IPO, and a robust exozyme therapy roadmap backed by AI, digital biomarkers, and value‑based pricing.
5 minutes to read